Article Text

Download PDFPDF

Original article
SABRE: a multicentre randomised control trial of nebulised hypertonic saline in infants hospitalised with acute bronchiolitis
  1. Mark L Everard1,
  2. Daniel Hind2,
  3. Kelechi Ugonna3,
  4. Jennifer Freeman4,
  5. Mike Bradburn2,
  6. Cindy L Cooper2,
  7. Elizabeth Cross2,
  8. Chin Maguire2,
  9. Hannah Cantrill2,
  10. John Alexander5,
  11. Paul S McNamara6
  12. on behalf of The SABRE Study Team
    1. 1University of Western Australia, Perth, Western Australia, Australia
    2. 2University of Sheffield, Sheffield, UK
    3. 3Sheffield Children's NHS Foundation Trust, Sheffield, UK
    4. 4University of Leeds, Leeds, UK
    5. 5University Hospital of North Staffordshire NHS Trust, Stoke–on–Trent, UK
    6. 6University of Liverpool, Liverpool, UK
    1. Correspondence to Dr Mark L Everard, School of Paediatrics and Child Health (SPACH), The University of Western Australia, 35 Stirling Highway, Crawley, Perth WA 6009, Australia; mark.everard{at}


    Aim Acute bronchiolitis is the commonest cause for hospitalisation in infancy. Supportive care remains the cornerstone of current management and no other therapy has been shown to influence the course of the disease. It has been suggested that adding nebulised hypertonic saline to usual care may shorten the duration of hospitalisation. To determine whether hypertonic saline does have beneficial effects we undertook an open, multi-centre parallel-group, pragmatic RCT in ten UK hospitals.

    Methods Infants admitted to hospital with a clinical diagnosis of acute bronchiolitis and requiring oxygen therapy were randomised to receive usual care alone or nebulised 3% hypertonic saline (HS) administered 6-hourly. Randomisation was within 4 h of admission. The primary outcome was time to being assessed as ‘fit’ for discharge with secondary outcomes including time to discharge, incidence of adverse events together with follow up to 28 days assessing patient centred health related outcomes.

    Results A total of 317 infants were recruited to the study. 158 infants were randomised to HS (141 analysed) and 159 to standard care (149 analysed). There was no difference between the two arms in time to being declared fit for discharge (hazard ratio: 0−95, 95% CI: 0.75−1.20) nor to actual discharge (hazard ratio: 0.97, 95% CI: 0.76−1.23). There was no difference in adverse events. One infant in the HS group developed bradycardia with desaturation.

    Conclusion This study does not support the use of nebulised HS in the treatment of acute bronchiolitis over usual care with minimal handlings. registration number NCT01469845.

    • Paediatric Lung Disaese
    • Viral infection
    • Nebuliser therapy

    This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles